In December, CELG’s Revlimid maintained its #1 market share position across all lines of treatment. Darzalex emerged as the #3 therapy in the 2nd line MM market with 17% share and remained in the #2 position with 32% share in 3rd line+. In December, Darzalex’s overall MM share stood at 9% vs. 6% a year ago. We estimate global Darzalex sales of ~$2B in 2018, up from $1.2B in 2017.
FIRE THE BRAND LEADS AND ALL MARKETERS ON THIS BRAND!
FIRE THE BRAND LEADS AND ALL MARKETERS ON THIS BRAND!